➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,143,972

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,143,972 protect, and when does it expire?

Patent 10,143,972 protects EVZIO and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,143,972
Title:Ultrafiltration membrane and a preparation method thereof
Abstract: The present invention provides an ultrafiltration membrane comprising a sulfone polymer membrane matrix with pores and an organic polymer sealing layer, wherein the pores are filled with nanoadsorbents. The present invention further provides a method for preparing the ultrafiltration membrane, which includes the following steps: (1) synthesizing nanoadsorbents; (2) preparing the sulfone polymer membrane matrix by immersion-precipitation phase inversion; and (3) immobilizing nanoadsorbents in the pores of the sulfone polymer membrane matrix by reverse filling, then sealing the pores with organic polymers to form a multifunctional ultrafiltration membrane. In the present invention, colloidal gold, polyethylene glycol molecules and Pb(II) ions (and so forth) are utilized as models of viruses, macromolecular organic pollutants, and small molecular pollutants, respectively. It is shown that the multifunctional ultrafiltration membrane allows for removal of multiple pollutants from water and can simultaneously remove multiple pollutants under low pressure.
Inventor(s): Li; Jiansheng (Jiangsu, CN), Pan; Shunlong (Jiangsu, CN), Fang; Xiaofeng (Jiangsu, CN), Wang; Lianjun (Jiangsu, CN), Sun; Xiuyun (Jiangsu, CN), Shen; Jinyou (Jiangsu, CN), Han; Weiqing (Jiangsu, CN), Liu; Xiaodong (Jiangsu, CN)
Application Number:15/540,260
Patent Claim Types:
see list of patent claims
Use; Formulation; Process;

Drugs Protected by US Patent 10,143,972

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 205787-001 Apr 3, 2014 DISCN Yes No   Start Trial   Start Trial USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,143,972

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
China2016 1 0044661Jan 22, 2016
PCT Information
PCT FiledJanuary 25, 2016PCT Application Number:PCT/CN2016/072041
PCT Publication Date:July 27, 2017PCT Publication Number: WO2017/124572

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.